Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Holding AVDL?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.03Last Year’s EPS
-$0.32Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -36.75%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlights significant progress and achievements, such as strong patient growth, new FDA approvals, and positive legal outcomes. However, challenges persist with patient persistency and ongoing litigation. The sentiment is overall positive, driven by consistent growth and strategic achievements, despite the noted challenges.Company Guidance
During the Q3 2024 earnings call for Avadel Pharmaceuticals, management provided detailed guidance on the ongoing commercial progress of LUMRYZ, highlighting several key metrics. As of September 30, the company had 2,300 active patients on therapy and achieved $50 million in net revenue for the quarter. The launch was notably marked by the addition of 700 new patients, with the fastest-growing segment being those new to oxybate therapy. The company also emphasized strong representation across all three patient segments: those switching from mixed salt oxybate products, new to oxybate patients, and previously treated and discontinued patients. Additionally, the expansion efforts included the FDA approval of LUMRYZ for pediatric patients aged 7 and older, and ongoing enrollment in the Phase III REVITALYZ study. On the financial side, Avadel reported a gross profit of $43.9 million, with expectations for positive cash flow in Q4, despite potential seasonal impacts. The company is also proactively addressing patient persistency by increasing the number of nurse care navigators and expanding their sales force to support both new and existing prescribers.Strong Patient Growth for LUMRYZ
2,300 active patients on therapy as of September 30, with 700 new patients initiating LUMRYZ therapy in Q3, resulting in $50 million in net revenue during the third quarter.
FDA Approval and Orphan Drug Exclusivity for Pediatric Use
Received FDA approval for LUMRYZ in treating cataplexy or excessive daytime sleepiness in pediatric patients 7 years and older with narcolepsy, along with a second orphan drug exclusivity award.
Successful Legal Outcomes
District of Columbia Court's favorable ruling affirming the FDA's approval and clinical superiority decision for LUMRYZ based on its unique once-nightly dosing profile.
Initiation of Phase III IH Trial
Enrollment is ongoing in the Phase III REVITALYZ study, evaluating LUMRYZ's potential clinical benefit in adults with idiopathic hypersomnia.
Positive Financial Results
Reported net revenue of $50 million and gross profit of $43.9 million for Q3, with a positive adjusted EBITDA of $6.1 million.
---
AVDL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AVDL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $16.30 | $13.15 | -19.33% |
| Aug 08, 2024 | $16.10 | $15.74 | -2.24% |
| May 08, 2024 | $18.18 | $16.25 | -10.62% |
| Mar 04, 2024 | $13.72 | $16.13 | +17.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Avadel Pharmaceuticals (AVDL) report earnings?
Avadel Pharmaceuticals (AVDL) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Avadel Pharmaceuticals (AVDL) earnings time?
Avadel Pharmaceuticals (AVDL) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVDL EPS forecast?
AVDL EPS forecast for the fiscal quarter 2024 (Q4) is -$0.03.
---